Patents by Inventor Aleksandr Aliper
Aleksandr Aliper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240174635Abstract: A TLR9 inhibitor includes a compound of general formula (I): wherein the meanings of the variables are explained in the specification, or a stereoisomeric form or a mixture of stereoisomeric forms, or pharmaceutically acceptable salts thereof. A pharmaceutical composition can include compounds of the invention, which can be used in a method for inhibiting TLR9 activity in vitro or in vivo. The method can be performed by administering the compound to a subject to inhibit TLR9 activity, which can be used to treat a disease or disorder associated with TLR9.Type: ApplicationFiled: October 2, 2023Publication date: May 30, 2024Inventors: Aleksandrs Zavoronkovs, Vladimir Aladinskiy, Aleksandr Aliper
-
Publication number: 20240152763Abstract: The proposed model is a Variational Autoencoder having a learnable prior that is parametrized with a Tensor Train (VAE-TTLP). The VAE-TTLP can be used to generate new objects, such as molecules, that have specific properties and that can have specific biological activity (when a molecule). The VAE-TTLP can be trained in a way with the Tensor Train so that the provided data may omit one or more properties of the object, and still result in an object with a desired property.Type: ApplicationFiled: December 13, 2023Publication date: May 9, 2024Inventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Daniil Polykovskiy, Maksim Kuznetsov, Yan Ivanenkov, Mark Veselov, Vladimir Aladinskiy, Evgeny Putin, Yuriy Volkov, Arip Asadulaev
-
Publication number: 20240092765Abstract: A method of inhibiting TNIK and/or MAP4K4 kinase can include: contacting the kinase with a compound of Formula A, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0. 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.Type: ApplicationFiled: July 6, 2023Publication date: March 21, 2024Inventors: Aleksandr Aliper, Vladimir Aladinskiy, Aleksandrs Zavoronkovs
-
Publication number: 20240092764Abstract: A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.Type: ApplicationFiled: August 30, 2023Publication date: March 21, 2024Inventors: Aleksandr Aliper, Vladimir Aladinskiy, Aleksandrs Zavoronkovs
-
Patent number: 11893498Abstract: The proposed model is a Variational Autoencoder having a learnable prior that is parametrized with a Tensor Train (VAE-TTLP). The VAE-TTLP can be used to generate new objects, such as molecules, that have specific properties and that can have specific biological activity (when a molecule). The VAE-TTLP can be trained in a way with the Tensor Train so that the provided data may omit one or more properties of the object, and still result in an object with a desired property.Type: GrantFiled: February 27, 2023Date of Patent: February 6, 2024Assignee: INSILICO MEDICINE IP LIMITEDInventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Daniil Polykovskiy, Maksim Kuznetsov, Yan Ivanenkov, Mark Veselov, Vladimir Aladinskiy, Evgeny Putin, Yuriy Volkov, Arip Asadulaev
-
Patent number: 11807622Abstract: A TLR9 inhibitor includes a compound of general formula (I): wherein the meanings of the variables are explained in the specification, or a stereoisomeric form or a mixture of stereoisomeric forms, or pharmaceutically acceptable salts thereof. A pharmaceutical composition can include compounds of the invention, which can be used in a method for inhibiting TLR9 activity in vitro or in vivo. The method can be performed by administering the compound to a subject to inhibit TLR9 activity, which can be used to treat a disease or disorder associated with TLR9.Type: GrantFiled: April 26, 2021Date of Patent: November 7, 2023Assignee: Insilico Medicine IP LimitedInventors: Aleksandrs Zavoronkovs, Vladimir Aladinskiy, Aleksandr Aliper
-
Patent number: 11795160Abstract: A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.Type: GrantFiled: February 20, 2020Date of Patent: October 24, 2023Assignee: Insilico Medicine IP LimitedInventors: Aleksandr Aliper, Vladimir Aladinskiy, Aleksandrs Zavoronkovs
-
Patent number: 11739078Abstract: A method of inhibiting TNIK and/or MAP4K4 kinase can include: contacting the kinase with a compound of Formula A, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.Type: GrantFiled: February 20, 2020Date of Patent: August 29, 2023Assignee: Insilico Medicine IP LimitedInventors: Aleksandr Aliper, Vladimir Aladinskiy, Aleksandrs Zavoronkovs
-
Publication number: 20230214662Abstract: The proposed model is a Variational Autoencoder having a learnable prior that is parametrized with a Tensor Train (VAE-TTLP). The VAE-TTLP can be used to generate new objects, such as molecules, that have specific properties and that can have specific biological activity (when a molecule). The VAE-TTLP can be trained in a way with the Tensor Train so that the provided data may omit one or more properties of the object, and still result in an object with a desired property.Type: ApplicationFiled: February 27, 2023Publication date: July 6, 2023Inventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Daniil Polykovskiy, Maksim Kuznetsov, Yan Ivanenkov, Mark Veselov, Vladimir Aladinskiy, Evgeny Putin, Yuriy Volkov, Arip Asadulaev
-
Publication number: 20230116632Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: ApplicationFiled: August 5, 2022Publication date: April 13, 2023Inventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Publication number: 20230115836Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: ApplicationFiled: August 5, 2022Publication date: April 13, 2023Inventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Patent number: 11593660Abstract: The proposed model is a Variational Autoencoder having a learnable prior that is parametrized with a Tensor Train (VAE-TTLP). The VAE-TTLP can be used to generate new objects, such as molecules, that have specific properties and that can have specific biological activity (when a molecule). The VAE-TTLP can be trained in a way with the Tensor Train so that the provided data may omit one or more properties of the object, and still result in an object with a desired property.Type: GrantFiled: September 18, 2018Date of Patent: February 28, 2023Assignee: INSILICO MEDICINE IP LIMITEDInventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Daniil Polykovskiy, Maksim Kuznetsov, Yan Ivanenkov, Mark Veselov, Vladimir Aladinskiy, Evgeny Putin, Yuriy Volkov, Arip Asadulaev
-
Patent number: 11530199Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: GrantFiled: February 23, 2022Date of Patent: December 20, 2022Assignee: Insilico Medicine IP LimitedInventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Patent number: 11530197Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: GrantFiled: February 23, 2022Date of Patent: December 20, 2022Assignee: Insilico Medicine IP LimitedInventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Publication number: 20220391709Abstract: A method for generating an object includes: providing a dataset having object data and condition data; processing the object data to obtain latent object data and latent object-condition data; processing the condition data to obtain latent condition data and latent condition-object data; processing the latent object data and the latent object-condition data to obtain generated object data; processing the latent condition data and latent condition-object data to obtain generated condition data; comparing the latent object-condition data to the latent condition-object data to determine a difference; processing the latent object data and latent condition data and one of the latent object-condition data or latent condition-object data to obtain a discriminator value; and selecting a selected object based on the generated object data.Type: ApplicationFiled: June 16, 2022Publication date: December 8, 2022Inventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Artur Kadurin, Daniil Polykovskiy, Rim Shayakhmetov
-
Publication number: 20220289723Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: ApplicationFiled: February 23, 2022Publication date: September 15, 2022Inventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Publication number: 20220274959Abstract: The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.Type: ApplicationFiled: February 23, 2022Publication date: September 1, 2022Inventors: Aleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
-
Patent number: 11403521Abstract: A method for generating an object includes: providing a dataset having object data and condition data; processing the object data to obtain latent object data and latent object-condition data; processing the condition data to obtain latent condition data and latent condition-object data; processing the latent object data and the latent object-condition data to obtain generated object data; processing the latent condition data and latent condition-object data to obtain generated condition data; comparing the latent object-condition data to the latent condition-object data to determine a difference; processing the latent object data and latent condition data and one of the latent object-condition data or latent condition-object data to obtain a discriminator value; and selecting a selected object based on the generated object data.Type: GrantFiled: June 22, 2018Date of Patent: August 2, 2022Assignee: INSILICO MEDICINE IP LIMITEDInventors: Aleksandr Aliper, Aleksandrs Zavoronkovs, Alexander Zhebrak, Artur Kadurin, Daniil Polykovskiy, Rim Shayakhmetov
-
Publication number: 20220119419Abstract: Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) and methods of using the compounds, e.g., in the treatment of immune disorders, inflammatory disorders, and cancer.Type: ApplicationFiled: September 17, 2021Publication date: April 21, 2022Inventors: Aleksandrs Zavoronkovs, Yan Ivanenkov, Aleksandr Aliper, Anton S. Vantskul
-
Publication number: 20210253553Abstract: A TLR9 inhibitor includes a compound of general formula (I): wherein the meanings of the variables are explained in the specification, or a stereoisomeric form or a mixture of stereoisomeric forms, or pharmaceutically acceptable salts thereof. A pharmaceutical composition can include compounds of the invention, which can be used in a method for inhibiting TLR9 activity in vitro or in vivo. The method can be performed by administering the compound to a subject to inhibit TLR9 activity, which can be used to treat a disease or disorder associated with TLR9.Type: ApplicationFiled: April 26, 2021Publication date: August 19, 2021Inventors: Aleksandrs Zavoronkovs, Vladimir Aladinskiy, Aleksandr Aliper